FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2279582904> ?p ?o ?g. }

• W2279582904 endingPage "7634" @default.
• W2279582904 startingPage "7634" @default.
• W2279582904 abstract "7634 Background: The NCCN Clinical Practice Guidelines (GL) allow many systemic therapy options for patients (pts) with mNSCLC. The primary aims of this analysis were to identify first-line regimens for the treatment of mNSCLC pts and examine concordance with NCCN NSCLC GL. Methods: The database was queried to identify pts with mNSCLC treated with first-line systemic therapy at 8 NCCN institutions presenting between September 2006 and March 2009. Pt characteristics, regimens utilized, and GL concordance were analyzed. Systemic therapy was categorized as cytotoxic doublet (CD), combination cytotoxic/targeted therapy (C/T), targeted therapy alone (T), or cytotoxic single agent (SA). Results: A total of 983 eligible pts were identified, as follows: 51% male; median age 64 years; performance status (PS) was documented in 77% (82% PS 0 or 1; 11% PS 2; 7% PS 3 or 4). There were 729 pts (74%) treated with systemic therapy, 123 (17%) of which participated in a clinical trial. Most common reasons for not receiving therapy were death prior to treatment (37%), therapy was not recommended (35%), or unknown (20%). For PS 3 or 4 pts not enrolled in a clinical trial, 20/48 (42%) received systemic therapy. Systemic therapy administered: 437 CD (60%), 139 C/T (19%), 94 T (13%), and 46 SA (6%). A platin-agent was used in 96% of CDs, with carboplatin in 83%. Paclitaxel (45%), gemcitabine (22%), docetaxel (15%) and pemetrexed (9%) were the most common partner agents. Of 600 pts with adenocarcinoma, 50 (8%) were treated with pemetrexed. Bevacizumab with carboplatin and either paclitaxel or docetaxel were the most common C/Ts (85% of C/T, 16% of all treated). Erlotinib was the most common T (92% of T, 12% of all treated). Analyses of EGFR mutation testing and concordance to NCCN NSCLC GLs are underway. Conclusions: The majority of pts with mNSCLC were treated with first-line systemic therapy and 17% participated in a clinical trial. Though not included in the NCCN GL prior to 2010, treatment of PS 3 or 4 pts and first-line therapy including erlotinib were observed. Few pts with adenocarcinoma received pemetrexed in the first-line setting. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ImClone Systems, Merck Genentech, Lilly Abbott Laboratories, Abraxis BioScience, Genentech, Lilly, Pfizer" @default.
• W2279582904 created "2016-06-24" @default.
• W2279582904 creator A5011567248 @default.
• W2279582904 creator A5015624396 @default.
• W2279582904 creator A5019357584 @default.
• W2279582904 creator A5026980497 @default.
• W2279582904 creator A5041342932 @default.
• W2279582904 creator A5066306817 @default.
• W2279582904 creator A5071145515 @default.
• W2279582904 creator A5071631687 @default.
• W2279582904 creator A5079014774 @default.
• W2279582904 creator A5087804549 @default.
• W2279582904 date "2010-05-20" @default.
• W2279582904 modified "2023-10-12" @default.
• W2279582904 title "First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project." @default.
• W2279582904 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.7634" @default.
• W2279582904 hasPublicationYear "2010" @default.
• W2279582904 type Work @default.
• W2279582904 sameAs 2279582904 @default.
• W2279582904 citedByCount "0" @default.
• W2279582904 crossrefType "journal-article" @default.
• W2279582904 hasAuthorship W2279582904A5011567248 @default.
• W2279582904 hasAuthorship W2279582904A5015624396 @default.
• W2279582904 hasAuthorship W2279582904A5019357584 @default.
• W2279582904 hasAuthorship W2279582904A5026980497 @default.
• W2279582904 hasAuthorship W2279582904A5041342932 @default.
• W2279582904 hasAuthorship W2279582904A5066306817 @default.
• W2279582904 hasAuthorship W2279582904A5071145515 @default.
• W2279582904 hasAuthorship W2279582904A5071631687 @default.
• W2279582904 hasAuthorship W2279582904A5079014774 @default.
• W2279582904 hasAuthorship W2279582904A5087804549 @default.
• W2279582904 hasConcept C121608353 @default.
• W2279582904 hasConcept C126322002 @default.
• W2279582904 hasConcept C143998085 @default.
• W2279582904 hasConcept C185926286 @default.
• W2279582904 hasConcept C2776256026 @default.
• W2279582904 hasConcept C2776694085 @default.
• W2279582904 hasConcept C2777240266 @default.
• W2279582904 hasConcept C2777802072 @default.
• W2279582904 hasConcept C2778239845 @default.
• W2279582904 hasConcept C2780258809 @default.
• W2279582904 hasConcept C2781190966 @default.
• W2279582904 hasConcept C2781230642 @default.
• W2279582904 hasConcept C2781451048 @default.
• W2279582904 hasConcept C530470458 @default.
• W2279582904 hasConcept C71924100 @default.
• W2279582904 hasConceptScore W2279582904C121608353 @default.
• W2279582904 hasConceptScore W2279582904C126322002 @default.
• W2279582904 hasConceptScore W2279582904C143998085 @default.
• W2279582904 hasConceptScore W2279582904C185926286 @default.
• W2279582904 hasConceptScore W2279582904C2776256026 @default.
• W2279582904 hasConceptScore W2279582904C2776694085 @default.
• W2279582904 hasConceptScore W2279582904C2777240266 @default.
• W2279582904 hasConceptScore W2279582904C2777802072 @default.
• W2279582904 hasConceptScore W2279582904C2778239845 @default.
• W2279582904 hasConceptScore W2279582904C2780258809 @default.
• W2279582904 hasConceptScore W2279582904C2781190966 @default.
• W2279582904 hasConceptScore W2279582904C2781230642 @default.
• W2279582904 hasConceptScore W2279582904C2781451048 @default.
• W2279582904 hasConceptScore W2279582904C530470458 @default.
• W2279582904 hasConceptScore W2279582904C71924100 @default.
• W2279582904 hasIssue "15_suppl" @default.
• W2279582904 hasLocation W22795829041 @default.
• W2279582904 hasOpenAccess W2279582904 @default.
• W2279582904 hasPrimaryLocation W22795829041 @default.
• W2279582904 hasRelatedWork W1893184243 @default.
• W2279582904 hasRelatedWork W2060263774 @default.
• W2279582904 hasRelatedWork W2126427337 @default.
• W2279582904 hasRelatedWork W2345450118 @default.
• W2279582904 hasRelatedWork W2351358978 @default.
• W2279582904 hasRelatedWork W2404692521 @default.
• W2279582904 hasRelatedWork W2439707001 @default.
• W2279582904 hasRelatedWork W2555706328 @default.
• W2279582904 hasRelatedWork W3127521146 @default.
• W2279582904 hasRelatedWork W4233984594 @default.
• W2279582904 hasVolume "28" @default.
• W2279582904 isParatext "false" @default.
• W2279582904 isRetracted "false" @default.
• W2279582904 magId "2279582904" @default.
• W2279582904 workType "article" @default.